دورية أكاديمية
أعرض في EDS

Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review.

التفاصيل البيبلوغرافية
العنوان: Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review.
المؤلفون: Caulley L; Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada. lcaulley@ohri.ca.; Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands. lcaulley@ohri.ca.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada. lcaulley@ohri.ca., Whelan J; Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada., Khoury M; Department of Otolaryngology-Head and Neck Surgery, Université de Montréal, Montreal, Canada., Mavedatnia D; Department of Undergraduate Medicine, University of Ottawa, Ottawa, Canada., Sahlollbey N; Department of Undergraduate Medicine, University of Ottawa, Ottawa, Canada., Amrani L; Department of Undergraduate Medicine, University of Ottawa, Ottawa, Canada., Eid A; Schulich School of Medicine & Dentistry, Western University, London, Canada., Doyle MA; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Department of Medicine, Endocrinology and Metabolism, University of Ottawa, Ottawa, Canada., Malcolm J; Department of Medicine, Endocrinology and Metabolism, University of Ottawa, Ottawa, Canada.; Knowledge Synthesis and Application Unit, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada., Alkherayf F; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Department of Neurosurgery, University of Ottawa, Ottawa, Canada., Ramsay T; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; Knowledge Synthesis and Application Unit, School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada., Moher D; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada.; Center for Journalology, The Ottawa Hospital Research Institute, Ottawa, ON, Canada., Johnson-Obaseki S; Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Schramm D; Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Hunink MGM; Department of Epidemiology and Biostatistics and Department of Radiology and Nuclear Medicine, Erasmus University Medical Center Rotterdam, Rotterdam, Netherlands.; Center for Health Decision Sciences, Harvard T.H. Chan School of Public Health, Boston, USA., Kilty SJ; Department of Otolaryngology-Head and Neck Surgery, The Ottawa Hospital, University of Ottawa, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
المصدر: Pituitary [Pituitary] 2023 Feb; Vol. 26 (1), pp. 73-93. Date of Electronic Publication: 2022 Nov 23.
نوع المنشور: Systematic Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Publishers Country of Publication: United States NLM ID: 9814578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7403 (Electronic) Linking ISSN: 1386341X NLM ISO Abbreviation: Pituitary Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Norwell, MA : Kluwer Academic Publishers, 1998-
مواضيع طبية MeSH: Pituitary Neoplasms*/surgery , Pituitary Neoplasms*/pathology , Lactotrophs*/pathology , Somatotrophs*/pathology , Adenoma*/surgery , Adenoma*/pathology, Humans ; Adolescent ; Adult ; Quality of Life ; Neoplasm Recurrence, Local/epidemiology ; Retrospective Studies
مستخلص: Context: Pituitary tumors are the third most common brain tumor and yet there is no standardization of the surveillance schedule and assessment modalities after transsphenoidal surgery.
Evidence Acquisition: OVID, EMBASE and the Cochrane Library databases were systematically screened from database inception to March 5, 2020. Inclusion and exclusion criteria were designed to capture studies examining detection of pituitary adenoma recurrence in patients 18 years of age and older following surgical resection with curative intent.
Evidence Synthesis: A total of 7936 abstracts were screened, with 812 articles reviewed in full text and 77 meeting inclusion criteria for data extraction. A pooled analysis demonstrated recurrence rates at 1 year, 5 years and 10 years for non-functioning pituitary adenomas (NFPA; N = 3533 participants) were 1%, 17%, and 33%, for prolactin-secreting adenomas (PSPA; N = 1295) were 6%, 21%, and 28%, and for growth-hormone pituitary adenomas (GHPA; N = 1257) were 3%, 8% and 13%, respectively. Rates of recurrence prior to 1 year were 0% for NFPA, 1-2% for PSPA and 0% for GHPA. The mean time to disease recurrence for NFPA, PSPA and GHPA were 4.25, 2.52 and 4.18 years, respectively.
Conclusions: This comprehensive review of the literature quantified the recurrence rates for commonly observed pituitary adenomas after transsphenoidal surgical resection with curative intent. Our findings suggest that surveillance within 1 year may be of low yield. Further clinical trials and cohort studies investigating cost-effectiveness of surveillance schedules and impact on quality of life of patients under surveillance will provide further insight to optimize follow-up.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Jagannathan J, Kanter A, Sheehan J, Jane J, Laws E (2007) Benign brain tumors: Sellar/parasellar tumors. Neurol Clin 25(4):1231–1249.
Villwock J, Villwock M, Deshaies E, Goyal P (2014) Significant increases of pituitary tumors and resections from 1993 to 2011. Int Forum Allergy Rhinol 4(9):767–770.
Daly A, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49(3):347–355.
Asa S, Mete O, Cusimano M et al (2021) Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 34(9):1634–1650.
Tumors of the pituitary gland (2017). In: Lloyd R, Osamura R, Kloppel G, Rosai J (eds) Who classification of tumours of endocrine organs, 4th edn. International Agency for Research on Cancer, Lyon, pp 11–64.
Molitch M (2017) Diagnosis and treatment of pituitary adenomas. JAMA 317(5):516–524.
Luongo N, Slivinski P, Smith A, Lovinaria D (2019) Neurosurgery and pituitary resection in cancer patients. Oncologic Critical Care 20:1683–1692.
Freda P, Wardlaw S (1999) Diagnosis and treatment of pituitary tumors. J Clin Endocrinol Metab 84(11):3859–3866.
Jane J Jr, Catalino M, Laws E Jr. Surgical Treatment of Pituitary Adenomas. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA). 2000.
Lucas J, Bodach M, Tumialan L et al (2016) Congress of Neurological Surgeons systematic review and evidence-based guideline on primary management of patients with nonfunctioning pituitary adenomas. Neurosurgery 79(4):E533-535.
Kreutzer J, Buslei R, Wallaschofski H et al (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11–18.
Asioli S, Righi A, Iommi M et al (2019) Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: Retrospective analysis on 566 patients from a tertiary care centre. Eur J Endocrinol 180(2):127–134.
Reddy R, Cudlip S, Byrne J, Karavitaki N, Wass J (2011) Can we ever stop imaging in surgically treated and radiotherapy-naïve patients with non-functioning pituitary adenoma? Eur J Endocrinol 165(5):739–744.
Kistka H, Kasl R, Nayeri A, Utz A, Weaver K, Chambless L (2015) Imaging of resected nonfunctioning pituitary adenomas: the cost of surveillance. J Neurol Surgery Part B 76(05):344–350.
Wilson L, Shin L, Ezzat S (2001) Longitudinal assessment of economic burden and clinical outcomes in acromegaly. Endocr Pract 7(3):170–180.
Raverot G, Burman P, McCormack A et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178(1):G1-24.
Lake M, Krook L, Cruz S (2013) Pituitary adenomas: an overview. Am Fam Phys 88(5):319–327.
Trouillas J, Roy P, Sturm N et al (2013) A new prognostic clinicopathological classfication of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135.
Ziu M, Dunn I, Hess C et al (2016) Congress of Neurological Surgeons systematic review and evidence-based guideline on posttreatment follow-up evaluation of patients with nonfunctioning pituitary adenomas. Neurosurgery 79(4):E541-543.
Mete O, Lopes M (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28(3):228–243.
Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V (2019) Cochrane handbook for systematic reviews of interventions, 2nd edn. Wiley, Chichester.
Moher D, Liberati A, Tetzlaff J, Altman D (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 151(4):264–269.
Page M, McKenzie J, Bossuyt P, The PRISMA et al (2020) statement: An updated guideline for reporting systematic reviews. Int J Surg 2021:88.
Perry A, Graffeo CS, Marcellino C, Pollock BE, Wetjen NM, Meyer FB (2018) Pediatric pituitary adenoma: case series, review of the literature, and a skull base treatment paradigm. J Neurol Surgery Part B 79(1):91–114.
Hlavica M, Bellut D, Lemm D, Schmid C, Bernays RL (2013) Impact of ultra-low-field intraoperative magnetic resonance imaging on extent of resection and frequency of tumor recurrence in 104 surgically treated nonfunctioning pituitary adenomas. World Neurosurg 79(1):99–109.
Batista R, Trarbach E, Marques M et al (2018) Nonfunctioning pituitary adenoma recurrence and its relationship with sex, size, and hormonal immunohistochemical profile. World Neurosurg 120:e241–e246.
Bradley K, Adams C, Potter C, Wheeler D, Anslow P, Burke C (1994) An audit of selected patients with non-functioning pituitary adenoma treated by transsphenoidal surgery without irradiation. Clin Endocrinol 41(5):655–659.
Brochier S, Galland F, Kujas M et al (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163(2):193–200.
Chang E, Sughrue M, Zada G, Wilson C, Blevins L, Kunwar S (2010) Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas. Pituitary 13(3):223–229.
Deng W-C, Yan J-L, Chuang C-C et al (2019) Adjuvant radiation therapy compared with observation alone for postoperative residual nonfunctional pituitary adenomas. World Neurosurg 128:e1024–e1033. https://doi.org/10.1016/j.wneu.2019.05.066. (PMID: 10.1016/j.wneu.2019.05.066)
Galm B, Martinez-Salazar E, Swearingen B et al (2018) MRI texture analysis as a predictor of tumor recurrence or progression in patients with clinically non-functioning pituitary adenomas. Eur J Endocrinol 179(3):191–198.
Gerges M, Rumalla K, Godil S et al (2021) Long-term outcomes after endoscopic endonasal surgery for nonfunctioning pituitary macroadenomas. J Neurosurg 134(2):535–546.
Przybylowski C, Dallapiazza R, Williams B et al (2017) Primary versus revision transsphenoidal resection for nonfunctioning pituitary macroadenomas: Matched Cohort Study. J Neurosurg 126(3):889–896.
Lillehei K, Kirschman D, Kleinschmidt-DeMasters B, Ridgway E (1998) Reassessment of the role of radiation therapy in the treatment of endocrine-inactive pituitary macroadenomas. Neurosurgery 43(3):432–438.
Liu C, Wu Y, Yu S et al (2017) Increased β-catenin and c-myc expression predict aggressive growth of non-functioning pituitary adenomas: an assessment using a tissue microarray-based approach. Mol Med Rep 15(4):1793–1799.
Maletkovic J, Dabbagh A, Zhang D et al (2019) Residual tumor confers a 10-fold increased risk of regrowth in clinically nonfunctioning pituitary tumors. J Endocr Soc 3(10):1931–1941. https://doi.org/10.1210/js.2019-00163. (PMID: 10.1210/js.2019-00163)
Nakao N, Itakura T (2011) Surgical outcome of the endoscopic endonasal approach for non-functioning giant pituitary adenoma. J Clin Neurosci 18(1):71–75.
Park S, Jang J, Lee Y, Kim J, Kim K, Kim Y (2017) Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection. Oncol Lett 14(6):7121–7130.
Turner H, Stratton I, Byrne J, Adams C, Wass J (1999) Audit of selected patients with nonfunctioning pituitary adenomas treated without irradiation - a follow-up study. Clin Endocrinol 51(3):281–284.
Webb K, Laurent J, Okonkwo D, Lopes M, Vance M, Laws E (2003) Clinical characteristics of silent corticotrophic adenomas and creation of an internet-accessible database to facilitate their multi-institutional study. Neurosurgery 53(5):1076–1085.
Zhang Z, Yang K, Xia Y, Meng X, Yu X (2019) High-field intraoperative magnetic resonance imaging increases extent of resection and progression-free survival for nonfunctioning pituitary adenomas. World Neurosurg 127:e925–e931.
Levy M, Robertson I, Khalk N et al (2018) Long-term follow-up of a large prospective cohort of patients with nonfunctioning pituitary adenomas: the outcome of a conservative management policy. Clin Endocrinol 89(3):354–359.
Tyrrell J, Lamborn K, Hannegan L, Applebury C, Wilson C (1999) Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 44(2):254–261.
Schaller B (2005) Gender-related differences in prolactinomas: a clinicopathological study. Neuroendocrinol Lett 26(2):152–159.
Camanni F, Ghigo E, Ciccarelli E et al (1983) Defective regulation of prolactin secretion after successful removal of prolactinomas. J Clin Endocrinol Metab 57(6):1270–1276.
Acquati S, Pizzocaro A, Tomei G et al (2001) A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma. J Neurol Sci 45(2):65–69.
Gordon D, Richards A, Bulloch R et al (1985) Prolactin dynamics and tumour size in the prediction of surgical outcome for Prolactinoma. QJM 54(2):141–151.
Hirohata T, Uozumi T, Mukada K et al (1991) Influence of pregnancy on the serum prolactin level following prolactinoma surgery. Acta Endocrinol 125(3):259–267.
Donegan D, Atkinson J, Jentoft M et al (2017) Surgical outcomes of prolactinomas in recent era: results of a heterogenous group. Endocr Pract 23(1):37–45.
Arafah B, Brodkey J, Pearson O (1986) Gradual recovery of lactotroph responsiveness to dynamic stimulation following surgical removal of prolactinomas: Long-term follow-up studies. Metabolism 35(10):905–912.
Thomson J, Gray C, Teasdale G (2002) Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: Lessons from long-term follow-up. Neurosurgery 50(1):36–40.
Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with Prolactinoma. N Engl J Med 309(5):280–283.
Merola B, Colao A, Panza N et al (1992) Clinical management of prolactinomas: a ten-Year experience. Med Oncol Tumor Pharmacother 9(2):93–99.
Massoud F, Serri O, Hardy J, Somma M, Beauregard H (1996) Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up. Surg Neurol 45(4):341–346.
Wiebe R, Kramer R, Hammond C (1979) Surgical treatment of prolactin-secreting microadenomas. Am J Obstet Gynecol 134(1):49–55.
Scanlon M, Peters J, Thomas J et al (1985) Management of selected patients with hyperprolactinaemia by partial hypophysectomy. BMJ 291(6508):1547–1550.
Rodman E, Molitch M, Post K, Biller B, Reichlin S (1984) Long-term follow-up of transsphenoidal selective adenomectomy for Prolactinoma. JAMA 252(7):921–924.
Ciccarelli E, Ghigo E, Miola C, Gandini G, Muller E, Camanni F (1990) Long-term follow-up of ‘cured’ prolactinoma patients after successful adenomectomy. Clin Endocrinol 32(5):583–592.
Bevan J, Adams C, Burke C et al (1987) Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including preoperative bromocriptine therapy. Clin Endocrinol 26(5):541–556.
Webster J, Page M, Bevan J, Richards S, Douglas-Jones A, Scanlon M (1992) Low recurrence rate after partial hypophysectomyfor prolactinoma: The predictive value ofdynamic prolactin function tests. Clin Endocrinol 36(1):35–44.
Schlechte J, Sherman B, Halmi N et al (1980) Prolactin-secreting pituitary tumors in Amenorrheic women: a comprehensive study. Endocr Rev 1(3):295–308.
Abosch A, Tyrrell J, Lamborn K, Hannegan L, Applebury C, Wilson C (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: Initial outcome and long-term results. J Clin Endocrinol Metab 83(10):3411–3418.
Beauregard C, Truong U, Hardy J, Serri O (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clin Endocrinol 58(1):86–91.
Biermasz N, Smit J, Van Dulken H, Roelfsema F (2002) Postoperative persistent thyrotrophin releasing hormone-induced growth hormone release predicts recurrence in patients with acromegaly. Clin Endocrinol 56(3):313–319.
Faglia G, Paracchi A, Ferrari C, Beck-Peccoz P (1978) Evaluation of the results of trans-sphenoidal surgery in acromegaly by assessment of the growth hormone response to thyrotrophin-releasing hormone. Clin Endocrinol 8(5):373–380.
Sheaves R, Jenkins P, Blackburn P et al (1996) Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure. Clin Endocrinol 45(4):407–413.
Swearingen B, Barker F, Katznelson L et al (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83(10):3419–3426.
Valdemarsson S, Ljunggren S, Bramnert M, Norrhamn O, Nordstrom C (2000) Early postoperative growth hormone levels: High predictive value for long-term outcome after surgery for acromegaly. J Intern Med 247(6):640–650.
Yamada S, Aiba T, Shishiba Y (1989) Postoperative prognostic indicators of control of acromegaly. Surg Neurol 31(1):14–19.
Annabestani Z, Mohajeri-Tehrani M, Tabatabaie-Malazy O et al (2011) Assessment of influencing factors on outcome of transsphenoidal surgery in Acromegalic patients. Int J Endocrinol Metab 9(4):360–363.
Babu H, Ortega A, Nuno M et al (2017) Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery 81(2):357–366.
Ronchi C, Varca V, Giavoli C et al (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90(3):1377–1382.
Serri O, Somma M, Comtois R et al (1985) Acromegaly: Biochemical assessment of cure after long term follow-up of transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 61(6):1185–1189.
Shimon I, Cohen Z, Ram Z, Hadani M (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 48(6):1239–1245.
Zirkzee E, Corssmit E, Biermasz N et al (2004) Pituitary magnetic resonance imaging is not required in the postoperative follow-up of acromegalic patients with long-term biochemical cure after transsphenoidal surgery. J Clin Endocrinol Metab 89(9):4320–4324.
Kristof R, Grote A, Redel L, Neuloh G, Klingmüller D, Schramm J (2010) The common consensus criteria have high predictive values for long-term postoperative acromegaly remission. Acta Neurochir 153(1):19–25.
Wagenmakers M, Netea-Maier R, van Lindert E, Pieters G, Grotenhuis A, Hermus A (2011) Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a growth hormone-secreting macroadenoma. Acta Neurochir 153(7):1391–1399.
Kremer P, Forsting M, Ranaei G et al (2002) Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir 144(5):433–443.
Berkmann S, Schlaffer S, Buchfelder M (2013) Tumor shrinkage after transsphenoidal surgery for nonfunctioning pituitary adenoma. J Neurosurg 119(6):1447–1452.
Dekkers O, Pereira A, Roelfsema F et al (2006) Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91(5):1796–1801.
Dallapiazza R, Grober Y, Starke R, Laws E, Jane J (2015) Long-term results of endonasal endoscopic transsphenoidal resection of nonfunctioning pituitary macroadenomas. Neurosurgery 76(1):42–53.
Noh T-W, Jeong H, Lee M-K, Kim T, Kim S, Lee E (2009) Predicting recurrence of nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 94(11):4406–4413.
Gondim J, Almeida J, de Albuquerque L, Gomes E, Schops M, Mota J (2015) Endoscopic endonasal transsphenoidal surgery in elderly patients with pituitary adenomas. J Neurosurg 123(1):31–38.
Zygourakis C, Imber B, Chen R et al (2016) Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas. J NeurolSurgery Part B 78(02):125–131.
Petruson B, Jakobsson K, Elfverson J, Bengtsson B (1995) Five-year follow-up of nonsecreting pituitary adenomas. Arch Otolaryngol Head Neck Surg 121(3):317–322.
Luque-Ramirez M, Paramo C, da Costa CV, García-Mayor R (2007) Cost of management of invasive growth hormone-secreting macroadenoma. J Endocrinoll Invest 30(7):541–545.
Roset M, Merino-Montero S, Luque-Ramírez M et al (2012) Cost of clinical management of acromegaly in Spain. Clin Drug Investig 32(4):235–245.
Giustina A, Barkan A, Casanueva F et al (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526–529.
Katznelson L, Laws E, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933–3951.
Amar A, Couldwell W, Chen J, Weiss M (2002) Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 97(2):307–314.
Casanueva F, Molitch M, Schlechte J et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65(2):265–273.
Penn M, Cardinal T, Zhang Y et al (2021) Cure and hormonal control after prolactinoma resection: Case series and systematic review. J Endocr Soc 5(10):15.
Roelfsema F, Biermasz N, Pereira A (2011) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71–83.
Nayak A, Cresswell J, Mariappan P (2021) Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer: a systematic review. Transl Androl Urol 10(6):2737–2749.
Thompson C, Charlson M, Schenkein E et al (2010) Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 21(11):2262–2266.
Kjeldsen B, Thorsen H, Walley D, Kronborg O (1999) Influence of follow-up on health-related quality of life after radical surgery for colorectal cancer. Scand J Gastroenterol 34(5):509–515.
Almeida JP, Stephens CC, Eschbacher JM, Felicella MM, Yuen KCJ, White WL, Mooney MA, Bernat AL, Mete O, Zadeh G, Gentili F, Little AS (2019) Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers. Pituitary 22(5):514–519. https://doi.org/10.1007/s11102-019-00981-9.
Bakhsheshian J, Wheeler S, Strickland BA, Pham MH, Rennert RC, Carmichael J, Weiss M, Zada G (2019) Surgical outcomes following repeat transsphenoidal surgery for nonfunctional pituitary adenomas: A retrospective comparative study. Oper Neurosurg (Hagerstown) 16(2):127–135. https://doi.org/10.1093/ons/opy078.
Berkmann S, Schlaffer S, Nimsky C, Fahlbusch R, Buchfelder M (2014) Intraoperative high-field MRI for transsphenoidal reoperations of nonfunctioning pituitary adenoma. J Neurosurg 121(5):1166–1175.
Hughes JD, Koeller K, Rinaldo L, Erickson D, Bancos I, Meyer FB, Atkinson J, Van Gompel JJ (2018) Beyond gross total and subtotal: Does volumetric resection matter in nonfunctioning pituitary macroadenomas? World Neurosurg 116:e733–e737. https://doi.org/10.1016/j.wneu.2018.05.077.
Berinder K, Stackenäs I, Akre O, Hirschberg AL, Hulting AL (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol (Oxf) 63(4):450–455. https://doi.org/10.1111/j.1365-2265.2005.02364.x.
Micko A, Vila G, Höftberger R, Knosp E, Wolfsberger S (2019) Endoscopic transsphenoidal surgery of microprolactinomas: a reappraisal of cure rate based on radiological criteria. Neurosurgery 85(4):508–515. https://doi.org/10.1093/neuros/nyy385.
Moberg E, af Trampe E, Wersäll J, Werner S (1991) Long-term effects of radiotherapy and bromocriptine treatment in patients with previous surgery for macroprolactinomas. Neurosurgery 29(2):200–204; discussion 204–205. https://doi.org/10.1097/00006123-199108000-00005.
Rush S, Donahue B, Cooper P, Lee C, Persky M, Newall J (1991) Prolactin reduction after combined therapy for prolactin macroadenomas. Neurosurgery 28(4):502–505. https://doi.org/10.1097/00006123-199104000-00003.
فهرسة مساهمة: Keywords: Endocrine; Gonadotroph adenoma; Non-functioning pituitary adenoma; Pituitary surgery; Postoperative; Prolactinoma
تواريخ الأحداث: Date Created: 20221124 Date Completed: 20230210 Latest Revision: 20230210
رمز التحديث: 20240628
DOI: 10.1007/s11102-022-01289-x
PMID: 36422846
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7403
DOI:10.1007/s11102-022-01289-x